Nexavar Approved to Treat Liver Cancer

November 19, 2007

The FDA has approved Bayer HealthCare and Onyx Pharmaceuticals’ supplemental new drug application for Nexavar tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

Nexavar (sorafenib) is the first approved systemic drug therapy for liver cancer, according to Bayer.

In Europe, Nexavar was approved for the treatment of HCC in October. The drug is approved in more than 60 countries to treat advanced kidney cancer.